Review: Hepatitis C protease and polymerase inhibitors in development

AIDS Patient Care and STDs

Volumn 22, Issue 6, 2008, Pages 449-457

  Liu Young, Gustine ^a   Kozal, Michael J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; BOCEPREVIR; CILUPREVIR; INTERFERON REGULATORY FACTOR 3; LIVER ENZYME; MONTIRELIN; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA2A; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VALOPICITABINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PYRIMIDINE NUCLEOSIDE;

ADD ON THERAPY; AMINO ACID SUBSTITUTION; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CARDIOTOXICITY; CHILL; CONTROL GROUP; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ENZYME BLOOD LEVEL; FATIGUE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERBILIRUBINEMIA; MIXED INFECTION; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; POLLAKISURIA; RASH; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VIRUS LOAD; VIRUS STRAIN; XEROSTOMIA; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MULTICENTER STUDIES AS TOPIC; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; PYRIMIDINE NUCLEOSIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47949084830     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0199     Document Type: Review

References (48)

1. www.who.int/mediacentre/factsheets. (Last accessed March 25, 2007).
2. www.cdc.gov/ncidod/diseases/hepatitis/c/fact. (Last accessed March 25, 2007).
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
4. Kadam JS, Talal AH. Changing treatment paradigms: Hepatitis C virus in HIV-infected patients. AIDS Patient Care STDs 2007;21:154-168.
5. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36(suppl 1):S21-S29.
6. McHutchinson JG, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
7. Fried MW, Shiffman M, Reddy K, et al. PegInterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
8. Seeff LB, Hoofnagle JH, Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-287.
9. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. PegInterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
10. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148.
11. Yerly D, Di Giammarino L, Bihl F, et al. Targets of emerging therapies for viral Hepatitis B and C. Expert Opin Ther Targets 2006;10:833-850.
12. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-189.
13. Reesink HW, Zeuzem S, Weegink C, et al. Rapid decline of viral DNA in hepatitis C patients treated with VX-950: A phase 1b, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
14. Kieffer T, Sarrazin C, Bartels D, et al. Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV. J Hepat 2006;44(suppl 2):S7.
15. Sulkowski M. Specific targeted antiviral therapy for hepatitis C. Curr Gastroenterol Rep 2007;9:5-13.
16. Reesink HW, Forestier N, Weegink CJ, et al. Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with PegInterferon alfa-2a. J Hepat 2006;44:S272.
17. Forestier N, Weegink C, Purdy S, et al. Current status of subjects receiving peg-interferon-alfa-2a (PEGIFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950), with PEG-IFN. Hepatology 2006;44:614A-615A.
18. Forestier N, Reesink H, Weegink C, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-648.
19. Modi A, Hoofnagle J. New therapies for hepatitis C. Hepatology 2007;46:615-617.
20. Rodriguez-Torres M, Lawitz E, Muir A, et al. Current status of subjects receiving peg-interferon-alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology 2006;44:532A.
21. Lawitz EJ, Rodriguez-Torres M, Muir A, et al. 28 days of the hepatitis C protease inhibitor VX-950, in combination with PEG-interferon-alfa-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006;131:950-951.
22. Kieffer T, Sarrazin C, Miller J, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639.
23. McHutchison JG, Everson GT, Gordon S, et al. Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon-alfa-2a and ribavirin in previously untreated subjects with hepatitis C. J Hepatol 2007;46(S1):S296.
24. Press release, Vertex Pharmaceuticals Cambridge, MA, July 24, 2007. Available at: http://www.vrtx. com/Pressreleases2007/pr072407.htm
25. Kieffer T, Zhou Y, Zhang, E, et al. Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1-infected patients. Hepatology 2007;46(suppl 1):862A.
26. Zeuzem S, Sarrazin C, Rouzier R, et al. Antiviral activity of SCH 503034, A HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha). Hepatology 2005;42:233A-234A.
27. Zeuzem S, Sarrazin C, Rouzier R, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 pegintron non-responders: Phase 1B results. Hepatology 2005;42:276A-277A.
28. Sarrazin C, Rouzier R, Wagner F, et al. SCH503034, a novel hepatitis C protease inhibitor, plus pegylated interferon alfa-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-1278.
29. Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. J Biol Chem 2006;281:8205-8215.
30. Tong X, Chase R, Skelton, A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38.
31. Beaulieu P. Finger loop inhibitors of the HCV NS5B polymerase: Discovery and prospects for new HCV therapy. Curr Opin Drug Discovery Dev 2006;9:618-626.
32. Godofsky E, Afdhal N, Rustgi V, et al. A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283, a novel antiviral treatment for hepatitis C. Gastroenterology 2004;126:A681.
33. Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype 1 infection: Results of a phase IIa multicenter trial. J Hepat 2005;42(S2):39-40.
34. Dieterich D, Lawitz E, Nguyen T, et al. Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naive patients with HCV-1 infection: First results from a phase IIb trial. J Hepat 2006;44:S271-S272.
35. Lawitz E, Nguyen T, Younes Z, et al. Clearance of HCV RNA with valopicitabine (NM 283) plus peg-interferon in treatment-naive patients with HCV-1 infection: Results at 24 and 48 weeks. J Hepat 2007;46(suppl 1):S9.
36. O'brien C, Godofsky E, Rodriguez-Torres, M, et al. Randomized trial of valopicitabine (NM 283), alone or with peg-interferon, vs retreatment with peg-interferon plus ribavirin (peg-IFN/RBV) in hepatitis C patients with previous non-response to Peg-IFn/RBV: First interim results. Hepatology 2005;42:234A.
37. Afdhal N, O'Brien C, Godofsky M, et al. Valopicitabine (NM 283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: One year results. J Hepat 2007; 46(suppl 1):S5.
38. Bichko V, Lallos L, Soubasakos M, et al. Valopicitabine (NM 283) is fully active against known HCV protease resistance mutations in vitro. J Hepat 2007;46(suppl 1):S163.
39. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007;20:23-38.
40. Ralston R, Bichko V, Chase R, et al. Combination of two hepatitis C virus inhibitors SCH503034 and NM107, provides enhanced anti-replicon activity and suppresses emergence of resistant replicons. J Hepat 2007;46 (suppl 1):S298-S299.
41. Press release, Idenix Pharmaceuticals July 13, 2007: Valopicitabine development program placed on clinical hold in the United States. Available at: www.ir.idenix.com
42. Roberts S, Cooksley G, Shaw D, et al. Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J Hepat 2006;44(suppl 2):S269.
43. Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006;351:349-359.
44. Chandra P, Raible D, Harper D, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus; preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Gastroenterology 2006; 130(suppl 2):A748.
45. Villano S, Howe A, Raible D, et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment naïve HCV-infected patients. Hepatology 2006;44(suppl 1):607A-608A.
46. Villano S, Raible D, Harper D, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naïve patients with chronic HCV. J Hepat 2007;46(suppl 1):S24.
47. Press release Viropharma August 10, 2007: Potential safety issue identified in ongoing phase 2 clinical study of HCV-796. Available at: www.viropharma.com
48. Rossignol JF, Elfert A, El-Gohary Y, et al. Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peg-interferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Hepatology 2007;46(suppl 1):316A.